NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Kiniksa Pharmaceuticals International, PLC KNSA
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$677.6M
▲ 60.1% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
11.7%
Net margin · FY25
8.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 677.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
9 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
11.7%
Return on equity, FY2025
ROE
Operating margin11.4%
Net margin8.7%
Return on assets8.8%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+45.5%
Net income
−31.5%
EPS, diluted
−33.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 763.6M
total assets, end of FY2025
Total assetsUSD 763.6M
EquityUSD 567.6M
CashUSD 165.6M
Current ratio3.79×
Equity funds 74% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.7
0.4
0.3
0.2
0.0
·
·
·
·
Operating income $B
0.1
−0.0
−0.0
0.0
−0.2
−0.2
−0.2
−0.1
−0.1
EBITDA $B
0.1
−0.0
−0.0
0.0
−0.2
−0.2
−0.2
−0.1
−0.1
Income tax $B
0.0
0.0
−0.0
−0.2
0.0
0.0
−0.0
−0.0
0.0
Net income $B
0.1
−0.0
0.0
0.2
−0.2
−0.2
−0.2
−0.1
−0.1
EPS, diluted $
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
−0
−0
ROE %
11.7
−9.8
3.4
63.1
−63.6
−60.1
−64.1
−108.9
·
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed